SEC Tracker
Get the app

Kura Oncology KURA

Kura Oncology reported a net loss of $70.22 million for the three months ended Sep 30, 2026.

Kura Oncology (KURA) filed a 10-Q with the SEC on Nov 10, 2026, 4:11 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $22.84 million for the three months ended Sep 30, 2026.
  2. Diluted EPS was -$0.78 for the three months ended Sep 30, 2026.
  3. Cash and equivalents were $57.94 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Kura Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

2 new risk factors · 1 removed

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$22.84M$20.87M+9.4%
Operating income and margin−$74.66M · -326.9%−$73.01M · -349.8%−2.3%, margin +22.9 pts
Net income−$70.22M−$68.33M−2.8%
Operating cash flow−$54.44M−$62.55M+13%
Cash$57.94M$70.24M−18%
New risk factors (2)
  • Prior to receiving approval, if any, to commercialize a product candidate in the United States or internationally, we or our collaborators must demonstrate to the satisfaction of the FDA and other regulatory authorities that such product candidate is safe and effective for its intended use. The results from…
  • On November 9, 2026, we entered into the Oberland Loan Agreement and the Royalty Participation Agreement and borrowed $50.0 million under the first tranche, or the Initial Advance. We may borrow additional Term Loans, subject to the applicable funding conditions. Draws under each of the second and third tranches are… +4 more paragraphs
Removed risk factors (1)
  • In November 2022, we entered into the Loan Agreement with the Lenders and Hercules, in its capacity as administrative agent and collateral agent for itself and the Lenders, providing for up to $125.0 million in a series of term loans, or Term Loans. Under the terms of the Loan Agreement, we borrowed $10.0 million of… +1 more paragraph

Data on this page was fetched . The filing on SEC.gov is the record.